Safety and Efficacy of Mycophenolic Acid Withdrawal With Conversion to Zortress (Everolimus) in Renal Transplant Recipients With BK Virus Infection

Trial Profile

Safety and Efficacy of Mycophenolic Acid Withdrawal With Conversion to Zortress (Everolimus) in Renal Transplant Recipients With BK Virus Infection

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolic acid; Prednisone; Tacrolimus
  • Indications Viral infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 27 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top